Characterizing the mechanism and the clinical relevance of the synthetic lethal interaction between STAT3 inhibition and HER2 overexpression in breast cancers

被引：1
|
作者：
Barrueco, Ruth Rodriguez [1 ]
Yu, Jiyang [1 ]
Alvarez, Mariano [1 ]
Castro, Veronica [1 ]
Marshall, Netonia [1 ]
Su, Ruoxi [1 ]
Castro, Laura [1 ]
Maurer, Matthew [1 ]
Califano, Andrea [1 ]
Silva, Jose M. [1 ]
机构：
[1] Columbia Univ, New York, NY USA
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-2761
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2761
引用
收藏
页数：2
相关论文
共 46 条
  • [21] ADGRF1 promotes tumorigenesis via the activation of STAT3 pathway in HER2+and triple-negative breast cancers
    Abdulkareem, Noor M.
    Bhat, Raksha
    Trivedi, Meghana V.
    FASEB JOURNAL, 2022, 36
  • [22] Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes
    Papanikolaou, Vassilis
    Stefanou, Nikolaos
    Dubos, Stephanie
    Papathanasiou, Ioanna
    Palianopoulou, Maria
    Valiakou, Vaia
    Tsezou, Aspasia
    CELLULAR ONCOLOGY, 2015, 38 (02) : 155 - 164
  • [23] Synergy of leptin/STAT3 with HER2 receptor induces tamoxifen resistance in breast cancer cells through regulation of apoptosis-related genes
    Vassilis Papanikolaou
    Nikolaos Stefanou
    Stephanie Dubos
    Ioanna Papathanasiou
    Maria Palianopoulou
    Vaia Valiakou
    Aspasia Tsezou
    Cellular Oncology, 2015, 38 : 155 - 164
  • [24] TrkA Interacts with and Phosphorylates STAT3 to Enhance Gene Transcription and Promote Breast Cancer Stem Cells in Triple-Negative and HER2-Enriched Breast Cancers
    Regua, Angelina T.
    Aguayo, Noah R.
    Jalboush, Sara Abu
    Doheny, Daniel L.
    Manore, Sara G.
    Zhu, Dongqin
    Wong, Grace L.
    Arrigo, Austin
    Wagner, Calvin J.
    Yu, Yang
    Thomas, Alexandra
    Chan, Michael D.
    Ruiz, Jimmy
    Jin, Guangxu
    Strowd, Roy
    Sun, Peiqing
    Lin, Jiayuh
    Lo, Hui-Wen
    CANCERS, 2021, 13 (10)
  • [25] Single domain antibody (SBT-100) inhibits growth of human HER2+and triple negative breast cancers (TNBC) in xenografts by binding STAT3 and P-STAT3
    Singh, S.
    Murillo, G.
    Chen, D.
    Singh, A.
    Singh, S.
    Singh, A.
    Mehta, R.
    Parihar, A.
    CANCER RESEARCH, 2017, 77
  • [26] Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers
    Rodriguez-Barrueco, Ruth
    Yu, Jiyang
    Saucedo-Cuevas, Laura P.
    Olivan, Mireia
    Llobet-Navas, David
    Putcha, Preeti
    Castro, Veronica
    Murga-Penas, Eva M.
    Collazo-Lorduy, Ana
    Castillo-Martin, Mireia
    Alvarez, Mariano
    Cordon-Cardo, Carlos
    Kalinsky, Kevin
    Maurer, Matthew
    Califano, Andrea
    Silva, Jose M.
    GENES & DEVELOPMENT, 2015, 29 (15) : 1631 - 1648
  • [27] Interaction between STAT3 and GLI1/tGLI1 oncogenic transcription factors promotes the aggressiveness of triple-negative breast cancers and HER2-enriched breast cancer (vol 37, pg 2502, 2018)
    Sirkisoon, Sherona R.
    Carpenter, Richard L.
    Rimkus, Tadas
    Anderson, Ashley
    Harrison, Alexandria
    Lange, Allison M.
    Jin, Guangxu
    Watabe, Kounosuke
    Lo, Hui-Wen
    ONCOGENE, 2024, 43 (30) : 2371 - 2371
  • [28] Study of inhibition effect of Herceptin on interaction between Heregulin and ErbB Receptors HER3/HER2 by single-molecule force spectroscopy
    Shi, Xiaoli
    Xu, Li
    Yu, Junping
    Fang, Xiaohong
    EXPERIMENTAL CELL RESEARCH, 2009, 315 (16) : 2847 - 2855
  • [29] Inhibition of the autocrine IL6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+breast cancers
    Silva, J.
    Rodriguez-Barrueco, R.
    Yu, J.
    Kalinsky, K.
    Maurer, M.
    Califano, A.
    CANCER RESEARCH, 2016, 76
  • [30] Evaluating the role of CDK4/6 inhibition on STAT3 activation in a transgenic mouse model of HER2-positive breast cancer
    Adesoye, Taiwo
    Luo, Linjie
    Bui, Tuyen
    Kim, Serena
    Wingate, Hannah
    Tripathy, Debu
    Hunt, Kelly
    Keyomarsi, Khandan
    CANCER RESEARCH, 2024, 84 (09)
12345